A Phase I/IIa multi-dose escalation study of BT062 in combination with Lenalidomide and Dexamethasone in subjects with relapsed or relapsed/refractory Multiple Myeloma
ID Number 14-0806Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this research study is to evaluate the dose limiting toxicities (side effects that are severe enough that you cannot take anymore drug at that dose) and the maximum tolerated dose (the highest dose that a human can take on an ongoing basis with minimal or mild side effects) as well as the anti-tumor activity of the compound in combination with lenalidomide/dexamethasone in subjects with relapsed or relapsed/refractory multiple myeloma.
Recruiting Patients: Yes